Royalty Pharma (NASDAQ: RPRX) financial statements
The consolidated income statement, balance sheet and cash flow statement of Royalty Pharma for its last 7 fiscal years, as filed with the regulator, in millions of US dollars. At the end of fiscal 2025 it had $19,621m in total assets and $9,715m in equity.
Income statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $2,378m | $2,264m | $2,355m | $2,237m | $2,289m | $2,122m | $1,814m |
| Operating profit | $1,560m | $1,292m | $1,492m | $307.1m | $1,431m | $1,595m | $2,623m |
| Finance costs | $307.7m | $225.5m | $187.2m | $188.0m | $166.1m | $157.1m | $268.6m |
| Profit before tax | $1,324m | $1,331m | $1,700m | $230.1m | $1,241m | $1,702m | $2,461m |
| Net profit | $770.9m | $859.0m | $1,135m | $42.8m | $619.7m | $975.0m | $2,349m |
| Earnings per share | $1.79 | $1.92 | $2.54 | $0.10 | $1.49 | $1.32 | — |
| Diluted earnings per share | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 | — |
| Depreciation and amortisation | $3.9m | $0.0m | $0.0m | $5.7m | $23.0m | $23.1m | $23.9m |
Balance sheet
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $19,621m | $18,223m | $16,382m | $16,813m | $17,516m | $16,020m | $12,450m |
| Current assets | $1,528m | $1,802m | $1,274m | $2,555m | $2,878m | $2,697m | $832.1m |
| Goodwill | $924.6m | $0.0m | — | — | — | — | — |
| Cash | $618.7m | $929.0m | $477.0m | $1,711m | $1,541m | $1,009m | $246.2m |
| Total liabilities | $9,906m | $7,880m | $6,298m | $7,288m | $7,267m | $6,124m | $6,308m |
| Current liabilities | $636.2m | $1,254m | $161.4m | $1,167m | $171.3m | $307.9m | $333.4m |
| Equity | $9,715m | $10,342m | $10,084m | $9,525m | $10,249m | $9,896m | $6,141m |
| Equity including minorities | $9,715m | $10,342m | $10,084m | $9,525m | $10,249m | $9,896m | $6,141m |
| Minority interests | $3,238m | $3,396m | $3,558m | $3,897m | $4,472m | $5,077m | $35.9m |
Cash flow statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $2,490m | $2,769m | $2,988m | $2,144m | $2,018m | $2,035m | $1,667m |
| Investing cash flow | −$1,614m | −$2,678m | −$2,073m | −$1,029m | −$1,870m | −$2,759m | −$2,154m |
| Financing cash flow | −$1,186m | $361.1m | −$2,149m | −$944.9m | $385.1m | $1,487m | −$1,192m |
Where each figure comes from
From the annual report (Form 10-K) that Royalty Pharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the Royalty Pharma page.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.